None listed
Conditions
Brief summary
Febrile malaria patients aged 6 months and above will be recruited to assess efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated P. falciparum infection. Artemether-lumefantrine will be given based on weight bands: one tablet to those weighing 5-14kg; 2 tablets for 15-24 kg; 3 tablets for 25-34 kg and four tablets for equal to or greater than 35 kg. Clinical and parasitological parameters will be monitored for 28 days followed-up to establish proportion of patients with treatment failure, frequency of adverse events and polymorphism of molecular markers for artemisinin resistance (K13).
Interventions
This was one arm prospective study to assess the efficacy and safety of artemether-lumefantrine (containing 20 mg artemether+ 120 mg lumefantrine in each tablet) given twice daily for three days according to the recommended weight bands as follows: 1 tablet to those weighing 5 to 14 kg; 2 tablets for 15 to 24 kg; 3 tablets for 25 to 34 kg and 4 tablets for equal or greater than 35 kg. The total target dose ranges are 5-24 mg/kg bw of artemether and 29-144 mg/kg bw of lumefantrine. All treatments
This was one arm prospective study to assess the efficacy and safety of artemether-lumefantrine (containing 20 mg artemether+ 120 mg lumefantrine in each tablet) given twice daily for three days according to the recommended weight bands as follows: 1 tablet to those weighing 5 to 14 kg; 2 tablets for 15 to 24 kg; 3 tablets for 25 to 34 kg and 4 tablets for equal or greater than 35 kg. The total target dose ranges are 5-24 mg/kg bw of artemether and 29-144 mg/kg bw of lumefantrine. All treatments will be given orally under direct supervision by the health worker. The patient will be followed up for 28 days
Sponsors
Ministry of National Health Services Regulations and Coordination
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
6 Months to No maximum
Healthy volunteers
No
Inclusion criteria
1. Aged between 6 months and above with the exception of 12-17 years old female minors and unmarried females above 18 years and above; 2. Mono-infection with P. falciparum detected by microscopy; 3. Parasitaemia of 500 – 200000 per microL asexual forms; 4. Presence of axillary or tympanic temperature greater or equal to 37.5 degrees centigrade or history of fever during the past 24 h; 5. Ability to swallow oral medication; 6. Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; 7. Informed consent from the patient or from a parent or guardian in the case of children aged less than 18 years; 8. Informed assent from any minor participant aged from 12 to 17 years; and 9. Consent for pregnancy testing from married female aged 18 years and above
Exclusion criteria
1. Presence of general danger signs in children aged under 12 years or signs of severe falciparum malaria according to the definitions of WHO; 2. Weight under 5 kg; 3. Mixed or mono-infection with another Plasmodium species detected by microscopy; 4. Presence of severe malnutrition defined as a child aged 6-60 months who has a mid-upper arm circumference below 115 mm); 5. Presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS); 6. Regular medication, which may interfere with antimalarial pharmacokinetics; 7. History of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s); 8. A positive pregnancy test or breastfeeding of married women aged 18 years and above; and 9. Unable to or unwilling to take pregnancy test or to use contraception for women of child-bearing age and who are sexually active.
Outcome results
None listed